Axsome Therapeutics, Inc. (AXSM) Stock Analysis

Analysts Think Axsome Therapeutics Stock Could Soar 35% Over the Next 12 Months. Is the Stock a No-Brainer Buy?

Fri, September 18, 2026 at 10:22 PM UTC 3 min read

Analysts are optimistic about Axsome Therapeutics (AXSM), projecting a potential 35% increase in the stock price over the next year. This positive outlook is driven by the company's promising pipeline and recent advancements in its treatment offerings, which could significantly impact revenue growth. Investors may view this as an attractive buying opportunity, given the anticipated market performance and the company's strategic position in the pharmaceutical sector.

Read full article →

AXSM Jumps 6% As Mizuho Calls Auvelity’s Alzheimer’s Launch A ‘Strong Start’

Fri, September 11, 2026 at 7:04 PM UTC 4 min read

AXSM shares surged 6% following Mizuho's positive assessment of Auvelity's launch for Alzheimer's treatment, describing it as a "strong start." This endorsement highlights the potential for robust sales growth and market acceptance of the drug, which could significantly impact AXSM's revenue and overall valuation. Investors may view this momentum as a signal of the company's promising future in the Alzheimer's treatment market.

Read full article →